Dr Adam Januszewski路 @AdamJanuszewski 路 X路路 5 hours agoScore70
Body 路 original
馃毃 #ESMO26 Another promising ADC in 2L EGFRm NSCLC!
Ph3 HER3 ADC ruzaltatug rezetecan vs chemo:
馃搱 PFS 8.3 vs 5.4m (HR 0.47)
馃搱 ORR 60% vs 34%
馃搱 OS HR 0.70 (immature)
鈿狅笍 ILD 2.4%
Competitive ADC landscape! More mature OS & global data needed.
8 views 路 0 likes 路 0 reposts 路 0 replies
Conference abstracts
LBA13matched by Proffered paper 1: Breast cancer, early and advanced stage
Trastuzumab rezetecan (SHR-A1811) in HER2-low advanced breast cancer (BC): A randomized, phase 3 study (HORIZON-Breast06)
https://esmocongress.esmo.orgSource: Dr Adam Januszewski 路 x.com